PMID- 23496668
OWN - NLM
STAT- MEDLINE
DCOM- 20130916
LR  - 20211021
IS  - 1744-8395 (Electronic)
IS  - 1476-0584 (Print)
IS  - 1476-0584 (Linking)
VI  - 12
IP  - 3
DP  - 2013 Mar
TI  - Dendritic cells in cancer immunotherapy: vaccines and combination 
      immunotherapies.
PG  - 285-95
LID - 10.1586/erv.13.22 [doi]
AB  - Dendritic cells (DCs) are specialized immunostimulatory cells involved in the 
      induction and regulation of immune responses. The feasibility of large-scale 
      ex vivo generation of DCs from patients' monocytes allows for therapeutic 
      application of ex vivo-cultured DCs to bypass the dysfunction of endogenous DCs, 
      restore immune surveillance, induce cancer regression or stabilization or delay 
      or prevent its recurrence. While the most common paradigm of the therapeutic 
      application of DCs reflects their use as cancer 'vaccines', additional and 
      potentially more effective possibilities include the use of patients' autologous 
      DCs as parts of more comprehensive therapies involving in vivo or ex vivo 
      induction of tumor-reactive T cells and the measures to counteract systemic and 
      local immunosuppression in tumor-bearing hosts. Ex vivo-cultured DCs can be 
      instructed to acquire distinct functions relevant for the induction of effective 
      cancer immunity (DC polarization), such as the induction of different effector 
      functions or different homing properties of tumor-specific T cells (delivery of 
      'signal 3' and 'signal 4'). These considerations highlight the importance of the 
      application of optimized conditions for the ex vivo culture of DCs and the 
      potential combination of DC therapies with additional immune interventions to 
      facilitate the entry of DC-induced T cells to tumor tissues and their local 
      antitumor functions.
FAU - Kalinski, Pawel
AU  - Kalinski P
AD  - Department of Surgery, University of Pittsburgh, Pittsburgh, PA, USA. 
      kalinskip@upmc.edu
FAU - Muthuswamy, Ravikumar
AU  - Muthuswamy R
FAU - Urban, Julie
AU  - Urban J
LA  - eng
GR  - P50 CA121973/CA/NCI NIH HHS/United States
GR  - R01 CA134633/CA/NCI NIH HHS/United States
GR  - CA132714/CA/NCI NIH HHS/United States
GR  - P01 CA132714/CA/NCI NIH HHS/United States
GR  - CA121973/CA/NCI NIH HHS/United States
GR  - CA134633/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Review
PL  - England
TA  - Expert Rev Vaccines
JT  - Expert review of vaccines
JID - 101155475
RN  - 0 (Cancer Vaccines)
SB  - IM
MH  - Cancer Vaccines/*immunology/*therapeutic use
MH  - Cells, Cultured
MH  - Dendritic Cells/cytology/*immunology
MH  - Drug Therapy, Combination
MH  - Humans
MH  - Immunotherapy/*methods
MH  - Neoplasms/immunology/*therapy
MH  - T-Lymphocytes/immunology
PMC - PMC6542562
MID - NIHMS1024199
EDAT- 2013/03/19 06:00
MHDA- 2013/09/17 06:00
PMCR- 2019/05/30
CRDT- 2013/03/19 06:00
PHST- 2013/03/19 06:00 [entrez]
PHST- 2013/03/19 06:00 [pubmed]
PHST- 2013/09/17 06:00 [medline]
PHST- 2019/05/30 00:00 [pmc-release]
AID - 10.1586/erv.13.22 [doi]
PST - ppublish
SO  - Expert Rev Vaccines. 2013 Mar;12(3):285-95. doi: 10.1586/erv.13.22.